AstraZeneca Targets Actavis In Latest Nexium IP Suit

Law360, New York (March 20, 2013, 3:23 PM EDT) -- AstraZeneca AB launched a suit Tuesday in New Jersey federal court accusing drugmaker Actavis Inc. of infringing five of its patents for the heartburn drug Nexium by seeking federal approval to make and sell a generic version of Nexium’s active ingredient.

AstraZeneca claims that Actavis recently filed an abbreviated new drug application with the U.S. Food and Drug Administration seeking approval to manufacture and sell a 40-milligram delayed-release version of the active ingredient esomeprazole magnesium well before the last of AstraZeneca’s patents for Nexium are due...
To view the full article, register now.